GlassScriptPhysician profile
Kathy Alcid
NPI 1093199606
$3,017.50
in general payments reported to CMS, 2019-2025
22 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $173 · 2021: $717 · 2022: $569 · 2023: $678 · 2024: $332 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,178 · Gift: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,178.36 |
| Gift | $134.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $562.66 | 2022-2025 | Tyrvaya, Ryzumvi, Tyrvaya |
| Sun Pharmaceutical Industries INC. | $516.85 | 2019-2025 | Cequa |
| Visionary Optics LLC | $499.75 | 2021-2023 | |
| Alcon Vision LLC | $370.25 | 2019-2024 | Wavelight Refractive Suite, Clareon, Rocklatan |
| Novartis Pharmaceuticals Corporation | $141.11 | 2020-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $125.61 | 2019-2025 | Tecnis Iol, Tecnis Iol |
| Glaukos Corporation | $112.88 | 2019-2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Biotissue Holdings INC. | $104.05 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $100.68 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $74.52 | 2022-2023 | Alrex, Zylet, Prolensa |
| Dompe US, INC. | $65.78 | 2021-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $63.09 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $52.77 | 2019 | |
| Rxsight INC | $42.76 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Abbvie INC. | $42.08 | 2023-2025 | Lumigan |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $31.39 | 2025 | Xdemvy |
| Shire North American Group INC | $24.86 | 2019 | |
| Allergan, INC. | $20.70 | 2022 | |
| Sight Sciences, INC. | $17.76 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $16.77 | 2020 | |
| Eyevance Pharmaceuticals LLC | $16.71 | 2019 | |
| Thea Pharma INC. | $14.47 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Alcid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.